News - Appointments

Steven Hildemann, a former executive at Merck KGaA, has been appointed chief medical officer at Ipsen SA, reporting directly to Aymeric Le Chatelier, the chief executive. He will be responsible for the company’s global medical strategy.

AlzeCure Pharma AB, a Swedish pharmaceutical company focused on Alzheimer’s disease and pain, has appointed Martin Jönsson as chief executive. He replaces Johan Sandin, a company founder, who will stay with the organisation as chief scientific officer.

Venkat Reddy has become chief scientific officer, and David Moffat, chief technology officer, at Macrophage Pharma Ltd as the company prepares to bring a candidate drug into the clinic. Macrophage is developing small molecule immunomodulators for cancer.

Karl Naegler, an experienced venture capitalist, has joined Wellington Partners as a managing partner to help grow the firm’s life science business.

David Moskowitz has been appointed to the newly created role as head of capital markets strategy and investor relations at Verona Pharma Plc. He joins as the company advances a new drug for chronic obstructive pulmonary disease in the clinic.

Cytox Ltd, a British company developing non-invasive tools to identify patients at risk of Alzheimer’s disease and dementia, has recruited Ian Gilham as new chairman of its board.

Joseph Bernardo has been appointed senior strategic advisor at Mobidiag Ltd, a molecular diagnostics company with headquarters in Finland. Mobidiag provides screens for detecting gastrointestinal pathogens, antibiotic resistance and infectious diseases.

Namir Hassan has been promoted to chief executive officer at Zelluna Immunotherapy AS from the position of chief scientific officer following the departure of Miguel Forte to head  Bone Therapeutics SA.

Miguel Forte has been appointed chief executive at Bone Therapeutics SA which is developing cell and biological therapies to treat bone diseases.

Julia P Gregory has been appointed to the board of directors of Freeline Therapeutics Ltd which is developing a gene therapy for haemophilia B.